Celltrion Inc., a leading pharmaceutical firm in South Korea, said Friday that its coronavirus antibody treatment substance has shown treatment efficacy in clinical trials. CT-P59 has been administered to 32 healthy volunteers who have not contracted COVID-19 since July after receiving approval for phase one trials from the Ministry of Food and Drug Safety. It...Read More
